Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $87.84 USD
Change Today +0.38 / 0.43%
Volume 1.0M
As of 8:04 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/15 - $88.15
52 Week Low
04/21/14 - $42.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a nonsteroidal anti-inflammatory drug analgesic. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

19,000 Employees
Last Reported Date: 02/12/15
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $477.4K
Senior Vice President of Operations
Total Annual Compensation: $464.7K
President of Hospira Medical Devices
Total Annual Compensation: $512.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $550.5K
Compensation as of Fiscal Year 2014.

hospira inc (HSP) Key Developments

Hospira, Inc. Announces Availability of INFLECTRA™ (Infliximab) in Canada

Hospira Inc. announced the availability of INFLECTRA™ (infliximab) in Canada. Approved by Health Canada, INFLECTRA is available to healthcare practitioners for the treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and plaque psoriasis. INFLECTRA is biosimilar to the reference product REMICADE® (infliximab).

Clinigen Group Plc Extends Foscavir U.S Distribution Contract with Hospira, Inc

Clinigen Group Plc announced the extension and renegotiation of the exclusive license and distribution agreement with Hospira Inc. for its anti-viral product Foscavir (foscarnet sodium) in the U.S. This is expected to be beneficial to both parties. The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.

Hospira Launches Remicade Biosimilar Inflectra in Additional European Countries

Hospira announced that it is launching its Remicade biosimilar Inflectra in at least 10 new European markets, nearly doubling the product's presence on the continent. Inflectra (infliximab) is the first biosimilar monoclonal antibody to be marketed in Europe, will soon be available in Austria, Sweden, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands and Spain. Inflectra mimics Janssen's Remicade (infliximab), which treats inflammatory diseases such as psoriatic and rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, plaque psoriasis and ulcerative colitis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $87.84 USD +0.38

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chugai Pharmaceutical Co Ltd ¥3,755 JPY +70.00
Cintas Corp $81.74 USD +0.36
Mallinckrodt PLC $123.12 USD +0.74
UCB SA €70.24 EUR +0.53
Zimmer Holdings Inc $115.92 USD +1.31
View Industry Companies

Industry Analysis


Industry Average

Valuation HSP Industry Range
Price/Earnings 44.8x
Price/Sales 3.3x
Price/Book 4.5x
Price/Cash Flow 45.2x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at